Pharmasset, Inc. (NASDAQ: VRUS) a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs to treat viral infections is up 86.18% premarket to $135.30, relative to a 52-week range of $20.49 – $88.52. Gilead Sciences, Inc. (NASDAQ: GILD) focuses on... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]